カート
- すべて
削除
(298)
JAK・STATシグナル
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
国 または地域 を選 ぶ
クロマチン・エピジェネティックAMPK
(118)
Aurora Kinase
(74)
DNA Methyltransferase
(34)
Epigenetic Reader Domain
(274)
HDAC
(196)
HIF
(65)
HIF/HIF Prolyl-Hydroxylase
(67)
Histone Acetyltransferase
(41)
Histone Demethylase
(81)
Histone Methyltransferase
(196)
HuR
(3)
JAK
(169)
Methionine Adenosyltransferase (MAT)
(10)
PAD
(10)
PARP
(140)
PKC
(157)
Pim
(35)
Sirtuin
(93)
JAK
The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.
- FedratinibT1995936091-26-8Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- ￥10,500
在庫 ありSizeQTY
使用 例 - RuxolitinibT1829941678-49-5Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
- ￥12,500
在庫 ありSizeQTY 使用 例 - KurarinoneT5S099334981-26-5Kurarinone, a flavanoid derived from shrub Sophora flavescens,Kurarinone exhibits anti-tumor, estrogenic, and anti-inflammatory activities, it also shows strong inhibitory effect on immune responses. Kurarinone may ameliorate chronic inflammatory skin diseases through the suppression of pathogenic CD4(+) T-cell differentiation and the overall immune response.
- ￥9,000
在庫 ありSizeQTY - RitlecitinibT53821792180-81-4Ritlecitinib (PF-06651600) is a potent JAK3-selective inhibitor (IC50: 33.1 nM).
- ￥9,000
在庫 ありSizeQTY - Ruxolitinib phosphateT30431092939-17-7Ruxolitinib phosphate (INCB018424)(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
- ￥10,000
在庫 ありSizeQTY 使用 例 - Cucurbitacin ITQ01962222-07-3Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.
- ￥18,000
在庫 ありSizeQTY 使用 例 - TAK-901T2709934541-31-8TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
- ￥15,500
在庫 ありSizeQTY 使用 例 - FosifidancitinibT386241237168-58-9Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.
- ￥34,000
在庫 ありSizeQTY - JI069T77672850019-35-1JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
- ￥45,000
在庫 ありSizeQTY
- JAK3iT276501918238-72-8
在庫 JAK3i is a selective covalent inhibitor of JAK3 kinase. JAK3i reveals two distinct temporal waves of STAT5 phosphorylation and more potently targets the second wave, which is required for cell cycle progression and T cell proliferation.- ￥80,500
在庫 ありSizeQTY - NVP-BSK805 2HCl (1092499-93-8(free base))T6294
在庫 NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over JAK1, JAK3 and TYK2.- ￥12,500
在庫 ありSizeQTY - WDR5-0103 hydrochloride[890190-22-4(free base)]T5140WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).
- ￥8,500
在庫 ありSizeQTY - GDC-0214T98261831144-46-7GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).
- ￥34,000
在庫 ありSizeQTY - WHI-P97 HClT4657LWHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays. WHI-P97 effectively inhibited the in vitro invasiveness of EGFR-positive human cancer cells in a concentration-dependent manner.
- ￥13,500
在庫 ありSizeQTY - TG-46T20743936091-15-5
在庫 TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.- ￥45,000
在庫 ありSizeQTY - JAK-STAT-IN-1T786071236666-76-4
在庫 JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.- ￥45,000
在庫 ありSizeQTY - ￥45,000
- SB1317 hydrochloride (1204918-72-8(free base))T4227SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
- ￥10,500
在庫 ありSizeQTY - JAK-IN-10T13571916741-98-5
在庫 JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.- ￥18,500
在庫 ありSizeQTY - ButyzamideT678941110767-45-7
在庫 Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.- ￥65,500
在庫 ありSizeQTY - GS-829845T679051257705-09-1
在庫 GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life than the parent.- ￥9,000
在庫 ありSizeQTY - JAK3/BTK-IN-1T98142674036-91-8
在庫 JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inhibited the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.- ￥305,500
SizeQTY - TG-89T20742936091-56-4
在庫 TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2μ M against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.- ￥13,000
在庫 ありSizeQTY - JAK-IN-5 hydrochlorideT11710L2751323-21-2
在庫 JAK-IN-5 hydrochloride is a JAK inhibitor [1].- ￥372,000
SizeQTY - IzencitinibT358982051918-33-1
在庫 Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.- ￥20,500
在庫 ありSizeQTY - ￥20,500
- JAK3/BTK-IN-2T98132674036-93-0
在庫 JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTk-in-2 has the potential to treat diseases associated with abnormal JAK3 and BTK activity.- ￥305,500
SizeQTY - JAK-IN-11T12549916742-11-5
在庫 JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.- ￥114,000
在庫 ありSizeQTY - MomelotinibT18491056634-68-4Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.
- ￥7,500
在庫 ありSizeQTY 使用 例 - SolcitinibT36201206163-45-2Solcitinib (GLPG-0778) (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.
- ￥7,500
在庫 ありSizeQTY 使用 例 - SB1317T26531204918-72-8SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
- ￥15,000
SizeQTY 使用 例 - AZD-1480T3069935666-88-9AZD1480 is a novel ATP-competitive JAK2 inhibitor (IC50: 0.26 nM), selectivity act against Tyk2 and JAK3, and to a smaller extent against JAK1. AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary
- ￥12,000
在庫 ありSizeQTY 使用 例 - CEP-33779T61221257704-57-6CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
- ￥9,000
在庫 ありSizeQTY 使用 例 - Pyridone 6T3080457081-03-7Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.
- ￥17,500
在庫 ありSizeQTY 使用 例 - DegrasynT6300856243-80-6Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
- ￥13,500
在庫 ありSizeQTY 使用 例 - PeficitinibT6933944118-01-8Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
- ￥14,000
約 35 daysSizeQTY 使用 例 - PacritinibT6020937272-79-2Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).
- ￥8,000
在庫 ありSizeQTY 使用 例 - Atractylenolide IT5S016773069-13-31. Atractylenolide-I has an anti-inflammatory effect by inhibiting TNF-
α and IL-6 production; ameliorates sepsis syndrome, liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. 2. Atractylenolide-I significantly sensitizes the res- ￥8,500
在庫 ありSizeQTY 使用 例 - AT9283T3068896466-04-9AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
- ￥9,000
在庫 ありSizeQTY 使用 例 - MubritinibT6124366017-09-6Mubritinib (TAK-165) (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM.
- ￥7,500
在庫 ありSizeQTY 使用 例 - BaricitinibT24851187594-09-7Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
- ￥10,000
在庫 ありSizeQTY 使用 例 - TofacitinibT6321477600-75-2Tofacitinib (Tasocitinib) is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.
- ￥7,000
在庫 ありSizeQTY 使用 例 - AG490T2600133550-30-8AG490 (Tyrphostin B42) is an inhibitor of EGFR (IC50: 0.1
μ M). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn, Lck, Syk, Btk, and Src.- ￥10,000
在庫 ありSizeQTY 使用 例 - FilgotinibT19291206161-97-8Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.
- ￥11,500
在庫 ありSizeQTY 使用 例 - WP1066T2156857064-38-1WP1066 is a inhibitor of JAK2 (IC50: 2.30
μ M) and STAT3 (IC50: 2.43μ M) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.- ￥10,000
在庫 ありSizeQTY 使用 例 - UpadacitinibT75031310726-60-3Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
- ￥9,000
在庫 ありSizeQTY 使用 例 - RO8191T22142691868-88-9RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.
- ￥9,000
在庫 ありSizeQTY 使用 例 - PP2T6266172889-27-9PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
- ￥9,000
在庫 ありSizeQTY 使用 例 - LFM-A13T6217244240-24-2LFM-A13（IC50=2.5
μ M）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.- ￥7,500
在庫 ありSizeQTY 使用 例 - WHI-P97T4657211555-05-4WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal.
- ￥7,500
在庫 ありSizeQTY 使用 例 - ItacitinibT39981334298-90-6Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.
- ￥10,500
在庫 ありSizeQTY 使用 例
1ページ目 へ
ページ of 4
- トップ
フィードバック
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.